Mutant hepatitis B viruses: a matter of academic interest only or a problem with far-reaching implications?
François
G
G
WHO Collaborating Centre for Prevention and Control of Viral Hepatitis, Department of Epidemiology and Social Medicine, Universiteit Antwerpen, Universiteitsplein 1, B-2610 Antwerpen, Belgium. guido.francois@uia.ua.ac.be
Kew
M
M
Van Damme
P
P
Mphahlele
M J
MJ
Meheus
A
A
D004259:DNA-Directed DNA Polymerase / Q000235:genetics; D014644:Genetic Variation; D016679:Genome, Viral; D005838:Genotype; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D006514:Hepatitis B Surface Antigens / Q000235:genetics; D017325:Hepatitis B Vaccines / Q000494:pharmacology; D006513:Hepatitis B e Antigens / Q000235:genetics; D006515:Hepatitis B virus / Q000145:classification / Q000235:genetics* / Q000276:immunology / Q000472:pathogenicity; D006801:Humans; D009154:Mutation; D011401:Promoter Regions, Genetic; D012703:Serotyping; D015534:Trans-Activators / Q000235:genetics; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology; D054334:Viral Regulatory and Accessory Proteins
D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D006513:Hepatitis B e Antigens; D015534:Trans-Activators; D014764:Viral Proteins; D054334:Viral Regulatory and Accessory Proteins; C057628:hepatitis B virus X protein; D004259:DNA-Directed DNA Polymerase